Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE-PD: IPX203 vs IR CD-LD in Parkinson's Disease
NCT03670953Phase 3Completed
- Sponsor
- Impax Laboratories
- Start
- Nov 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of levodopa + carbidopa in Parkinson's disease (PD) (2 arms), sponsored by Impax Laboratories. Primary endpoint: Mean Change From Baseline in Good On Time Per Day at Week 20. Started Nov 2018; status: completed.
02
Drugs
levodopa + carbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03670953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670953.